Cyclin D1 over-expression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3β and ERK1/2 in mouse hepatic carcinogenesis

Carcinogenesis

Volumn 24, Issue 3, 2003, Pages 435-442

  Gotoh, Junichi ^a   Obata, Masahiko ^a   Yoshie, Masumi ^a   Kasai, Shinichi ^a   Ogawa, Katsuhiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B;

CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; STAINING; T LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYTOSKELETAL PROTEINS; DNA PRIMERS; GENES, RAS; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TRANS-ACTIVATORS;

EID: 0345700813     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/24.3.435     Document Type: Review

References (59)

1. Murray,C.J. and Lopez,A.D. (1997) Mortality by cause for eight regions of the world: global burden of disease study. Lancet, 349, 1269-1276.
2. de La Coste,A., Romagnolo,B., Billuart,P. et al. (1998) Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA, 95, 8847-8851.
3. Miyoshi,Y., Iwao,K., Nagasawa,Y., Aihara,T., Sasaki,Y., Imaoka,S., Murata,M., Shimano,T. and Nakamura,Y. (1998) Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 58, 2524-2527.
4. Ogawa,K., Yamada,Y., Kishibe,K., Ishizaki,K. and Tokusashi,Y. (1999) β-Catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res., 59, 1830-1833.
5. Devereux,T.R., Anna,C.H., Foley,J.F., White,C.M., Sills,R.C. and Barrett,J.C. (1999) Mutation of β-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene, 18, 4726-4733.
6. Tsujiuchi,T., Tsutsumi,M., Sasaki,Y., Takahama,M. and Konishi,Y. (1999) Different frequencies and patterns of β-catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-amino acid-defined diet in rats. Cancer Res., 59, 3904-3907.
7. Yamada,Y., Yoshimi,N., Sugie,S., Suzui,M., Matsunaga,K., Kawabata,K., Hara,A. and Mori,H. (1999) β-Catenin (Ctnnbl) gene mutations in diethylnitrosamine (DEN)-induced liver tumors in male F344 rats. Jpn. J. Cancer Res., 90, 824-828.
8. Anna,C.H., Sills,R.C., Foley,J.F., Stockton,P.S., Ton,T.V. and Devereux, T.R. (2000) β-Catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res., 60, 2864-2868.
9. Calvisi,D.F., Factor,V.M., Loi,R. and Thorgeirsson,S.S. (2001) Activation of β-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res., 61, 2085-2091.
10. Polakis,P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
11. Wong,N.A.C.S. and Pignatelli,M. (2002) β-Catenin - a linchpin in colorectal carcinogenesis? Am. J. Pathol., 160, 389-401.
12. Ozturk,M. (1999) Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis., 19, 235-242.
13. Tetsu,O. and McCormick,F. (1999) β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-426.
14. Shtutman,M., Zhurinsky,J., Simcha,I., Albanese,C., D'Amico,M., Pestell, R. and Ben-Ze'ev,A. (1999) The cyclin D1 gene is a target of the β-catenin/ LEF-1 pathway. Proc. Natl Acad. Sci. USA, 96, 5522-5527.
15. Lin,S.Y., Xia,W., Wang,J.C., Kwong,K.Y., Spohn,B., Wen, Y., Pestell,R.G. and Hung,M.C. (2000) β-Catenin, a novel prognostic marker for breast cancer: its role in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA, 97, 4262-4266.
16. Albanese,C., Johnson,J., Watanabe,G., Eklund,N., Vu,D., Arnold,A. and Pestell,R.G. (1995) Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem., 270, 23589-23597.
17. KIP1. Mol. Cell Biol., 17, 3850-3857.
18. Kerkhoff,E. and Rapp,U.R. (1997) Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell Biol., 17, 2576-2586.
19. 1 phase. Biochem. J., 326, 61-68.
20. Lavoie,J.N., L'Allemain,G., Brunet,A., Muller,R. and Pouyssegur, J. (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem., 271, 20608-20616.
21. Treinies,I., Paterson,H.F., Hooper,S., Wilson,R. and Marshall,C.J. (1999) Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal to stimulate DNA synthesis. Mol. Cell. Biol., 19, 321-329.
22. KiP1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl Acad. Sci. USA, 95, 1091-1096.
23. Hazan,R.B. and Norton,L. (1998) The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J. Biol. Chem., 273, 9078-9084.
24. Hiscox,S. and Jiang,W.G. (1999) Hepatocyte growth factor disrupts epithelial tumour cell-cell adhesion: involvement of β-catenin. Anticancer Res., 19, 509-517.
25. Playford,M.P., Bicknell,D., Bodmer,W.F. and Macaulay,V.M. (2000) Insulin-like growth factor 1 regulates the location, stability and transcriptional activity of β-catenin. Proc. Natl Acad. Sci., 22, 12103-12108.
26. Kinch,M.S., Clark,G.J., Der,C.J. and Burridge,K. (1995) Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J. Cell Biol., 130, 461-471.
27. Espada,J., Perez-Moreno,M., Braga,V.M., Rodriguez-Viciana,P. and Cano,A. (1999) H-ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of β-catenin in epidermal keratinocytes. J. Cell Biol., 146, 967-980.
28. Desbois-Mouthon,C., Cadoret,A., Blivet-Van Eggelpoel,M.J., Bertrand,F., Cherqui,G., Perret,C. and Capeau,J. (2001) Insulin and IGF-1 stimulate the β-catenin pathway through two-signalling cascades involving GSK3β inhibition and Ras activation. Oncogene, 20, 252-259.
29. Monick,M.M., Carter,A.B., Robeff,P.K., Flaherty,D.M., Peterson,M.W. and Hunninghake,G.W. (2001) Lipopolysaccaride activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of β-catenin. J. Immunol., 166, 4717-4720.
30. Diehl,J.A., Cheng,M., Roussel,M.F. and Sherr,C.J. (1998) Glycogen synthetase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
31. Tang,O., Gonzales,M., Inoue,H. and Bowden,G.T. (2001) Roles of Akt and glycogen synthetase kinase 3β in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res., 61, 4329-4332.
32. Chen,E.Y., Mazure,N.M., Cooper,J.A. and Giaccia,A.J. (2001) Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthetase kinase-3 inactivation. Cancer Res., 61, 2429-2433.
33. Chen,R.H., Ding,W.V. and McCormick,F. (2000) Wnt signaling to β-catenin involves two interactive components. Glycogen synthase kinase-3β inhibition and activation of protein kinase C. J. Biol. Chem., 275, 17894-17899.
34. Reynolds,H.S., Stowers,S.J., Patterson,R.M., Maronpot,R.R., Aaronson,S.A. and Anderson,M.W. (1987) Activated oncogens in B6C3F1 mouse liver tumors: implications for risk assessment. Science, 237, 1309-1316.
35. Maronpot,R.R., Fox,T., Malarkey,D.E. and Goldsworthy,T.L. (1995) Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology, 101, 125-156.
36. Romach,E.H., Goldsworthy,T.L., Maronpot,R.R. and Fox,T.R. (1997) Altered gene expression in spontaneous hepatocellular carcinomas from male B6C3F1 mice. Mol. Carcinogen., 19, 31-38.
37. Frith,C.H. and Ward,J.M. (1979) A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol., 3, 329-351.
38. Ogawa,K., Osanai,M., Obata,M., Ishizaki,K. and Kamiya,K. (1999) Gain of chromosomes 15 and 19 is frequent in both mouse hepatocellular carcinoma cell lines and primary tumors, but loss of chromosomes 4 and 12 is detected only in the cell lines. Carcinogenesis, 20, 2083-2088.
39. Satoh,S., Daigo,Y., Furukawa,Y. et al. (2000) AXIN1 mutations in hepatocellular carcinomas and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet., 24, 245-250.
40. Andrews,N.C. and Faller,D.V. (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19, 2499.
41. Roose,J., Molenaar,M., Peterson,J., Hurenkamp,J., Brantjes,H., Moerer,P., van de Wetering,M., Destree,O. and Clevers,H. (1998) The xenopus Wnt effector XTcf-3 interacts with Grouchou-related transcriptional repressors. Nature, 395, 608-612.
42. Woodgett,J.R. (2001) Judging a protein by more than its name:GSK3β. www.stke.org/cgi/content/full/OCsigtrans;2001/100/re12.
43. Pap,M. and Cooper,G.M. (1998) Role of glycogen synthetase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem., 273, 19929-19932.
44. Hoeflick,K.P., Luo,J., Rubie,E.A., Tsao,M.-S., Jin,O. and Woodgett,J.R. (2000) Requirement for glycogen synthetase kinase 3β in cell survival and NFκB activation. Nature, 406, 86-90.
45. Li,L., Yuan,H., Weaver,C.D., Mao,J., Farr,G.H. 3rd, Sussman,D.J., Jonkers,J., Kimelman,D. and Wu,D. (1999) Axin and Frat1 interact with Dv1 and GSK, bridging Dv1 to GSK in Wnt-mediated regulation of LEF1. EMBO J., 18, 4233-4240.
46. Hovanes,K., Li,T.W., Munguia,J.E., Truong,T., Milovanovic,T., Lawrence Marsh,J., Holcombe,R.F. and Waterman M.L. (2001) β-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nature Genet., 28, 53-57.
47. Roose,J., Huls,G., van Beest,M., Moerer,P., van der Horn,K., Goldschmeding,R., Logtenberg,T. and Clevers,H. (1999) Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science, 285, 1923-1926.
48. Ishitani,T., Ninomiya-Tsuji,J., Nagai,S. et al. (1999) The TAK1-NLK-MAPK-related pathway antagonizes signaling between β-catenin and trascription factor TCF. Nature, 399, 798-802.
49. Sadot,E., Simcha,I., Shtutman,M., Ben-Ze'ev,A. and Geiger,B. (1998) Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc. Natl Acad. Sci. USA, 95, 15339-15344.
50. Orsulic,S., Huber,O., Aberle,H., Arnold,S. and Kemler,R. (1999) E-cadherin binding prevents β-catenin nuclear localization and β-catenin/ LEF-1 mediated transactivation. J. Cell Sci., 112, 1237-1245.
51. Ooasa,T., Karasaki,H., Kanda,H., Nomura,K., Kitagawa,K. and Ogawa,K. (1998) Loss of imprinting of the insulin-like growth factor II gene in mouse hepatocellular carcinoma cell lines. Mol. Carcinogen, 23, 248-253.
52. Schiemacher,P., Held,W.A., Yang,D., Chisari,F.V., Rustum,Y. and Rogler,C.E. (1992) Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res., 52, 2549-2556.
53. Haddad,R. and Held,W.A. (1997) Genomic imprinting and IGF2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res., 57, 4615-4623.
54. Bissonnette,M., Khare,S., von Lintig,F.C. et al. (2000) Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2 and cyclin D1. Cancer Res., 60, 4602-4609.
55. Tada,M., Ohashi,M., Shiratori,Y., Okudaira,T., Komatsu,Y., Kawabe,T., Yoshida,H., Machinami,R., Kishi K. and Omata,M. (1996) Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology, 110, 227-231.
56. Terhune,P.G., Phifer,D.M., Tosteson,T.D. and Longnecker,D.S. (1998) K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol. Biomark. Prev., 7, 515-521.
57. Johnson,L., Mercer,K., Greenbaum,D., Bronson,R.T., Crowley,D., Tuveson,D.A. and Jacks,T. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 410, 1111-1116.
58. INK4a. Cell, 88, 593-602.
59. Umeda,T., Yamamoto,T., Kajino,K. and Hino,O. (2000) β-catenin mutations are absent in hepatocellular carcinomas of SV-40 T antigen in transgenic mice. Int. J. Oncol., 16, 1133-1136.